On February 8, 2013, a group of shareholders submitted a request in
writing to the Board of Directors of Diamyd Medical that the Board
convene an extraordinary General Meeting to address their proposal that
Diamyd Medical enter into immediate liquidation. The shareholders
claimed to represent 8,883,351 Series B shares in Diamyd, corresponding
to about 21 percent of the votes and 30 percent of the total number of
In addition to the proposed liquidation, the group of shareholders
proposes that the General Meeting elect a new Board of Directors, that
the company change its name to Diamyd Sverige AB (publ) and that the
General Meeting submit instructions to the Board to establish a wholly
owned subsidiary, which is to have the same number of shares as Diamyd
and only one class of share. Diamyd should transfer all of its share
holdings and about SEK 40,000,000 in cash to this subsidiary.
Due to this request, the Board of Directors has decided to convene an
Extraordinary General Meeting on Wednesday, March 13, 2013. Summons will
be published in Post- och Inrikes Tidningar on February 13, 2013. The
summons and the letter from the shareholders is available at Diamyd's
About Diamyd Medical
Diamyd Medical was founded in 1996 and is active in the field of
pharmaceutical development. Diamyd Medical is headquartered in
Stockholm, Sweden. The Company's development project consists of the
protein GAD for the treatment and prevention of autoimmune diabetes. A
Swedish researcher-initiated Phase II study is ongoing to evaluate
whether GAD can prevent type 1 diabetes in children who are at high risk
of developing the disease.
Diamyd Medical also has holdings in the gene therapy company Periphagen
Holdings, Inc. (USA), the vaccine company Protein Sciences Corporation
(USA) and the diagnostics company Mercodia AB (Sweden).
Diamyd shares are listed on Nasdaq OMX (segment Small Cap) in Stockholm
(ticker: DIAM B) and on OTCQX in the US (ticker: DMYDY) administered by
the Pink OTC Markets and the Bank of New York Mellon (PAL). Further
information is available on the Company's website: www.diamyd.com.
This information is disclosed in accordance with the Swedish
Securities Markets Act, the Swedish Financial Instruments Trading Act,
or the requirements stated in the listing agreements.
Diamyd Medical AB (publ)
Karlavägen 108, SE-115 26 Stockholm, Sweden. Phone: +46 8 661 00 26,
Fax: +46 8 661 63 68E-mail: firstname.lastname@example.org.
Reg. no: 556530-1420
This information was brought to you by Cision http://www.cisionwire.com
[ Back To NFVZone's Homepage ]